GERN vs IMVT vs KYMR vs JNJ

For growth investors, Geron Corporation (GERN) is the stronger pick with 138.

8% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Johnson & Johnson (JNJ) offers the better valuation at 38. 4x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Geron Corporation (GERN) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to +9. 8% for Geron Corporation (GERN). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus GERN's -47. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Geron Corporation's 1. 89β — meaning GERN is approximately 3219% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 111% for Geron Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Geron Corporation (GERN) is pulling ahead at 138.

8% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Geron Corporation grew EPS 51. 9% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, GERN leads at 575. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for GERN: 303.

4% to $5. 89.

In this comparison, JNJ (2.

2% yield) pays a dividend. GERN, IMVT, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Geron Corporation (GERN) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, GERN: -47. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GERN is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while GERN, IMVT, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.